Federal Reserve

  • Most Popular
  • Most Shared

REUTERS SHOWCASE

Monsoon Floods

Monsoon Floods

Death toll in Uttarakhand monsoon floods crosses 150  Full Article 

Auto Market

Auto Market

Tata Motors upgrades cars as rivals launch new ones.  Full Article 

EU Fines Ranbaxy

EU Fines Ranbaxy

EU fines Ranbaxy, others for blocking cheaper drugs.  Full Article 

Business Optimism

Business Optimism

Asian businesses optimistic; sentiment in India falls.  Full Article 

Financing Trouble

Financing Trouble

U.S. court lets stand Ex-Im Bank loan for Air India.  Full Article 

Euro Economy

Euro Economy

Half-way to lost decade, Europe's growth task as tough as ever.  Full Article 

Buy, Sell or Hold?

Buy, Sell or Hold?

Confused while buying stocks? Get buy, sell or hold recommendations from VantageTrade.  Full Coverage 

Reuters India Mobile

Reuters India Mobile

Get the latest news on the go. Visit Reuters India on your mobile device.  Full Coverage 

Sun Pharma gains on U.S. nod for cancer drug

Related Topics

Stocks

   
A pharmacist gives free medicine provided by the government, to a patient inside a government hospital in Kolkata July 3, 2012. REUTERS/Rupak De Chowdhuri/Files

A pharmacist gives free medicine provided by the government, to a patient inside a government hospital in Kolkata July 3, 2012.

Credit: Reuters/Rupak De Chowdhuri/Files

Tue Feb 5, 2013 12:55pm IST

Reuters Market Eye - Shares in Sun Pharmaceutical Industries Ltd (SUN.NS) rose as much as 4.5 percent after the U.S. Food and Drug Administration approved its generic version of ovarian cancer drug Doxil made by Johnson & Johnson (JNJ.N) in the U.S. market.

"Doxil generic approval came in as a positive surprise. This would add US$70-$100m in high margin sales for FY14 until further generic competition comes in," CLSA said in a note on Tuesday.

Shares in the drugmaker also gained after subsidiary Taro Pharmaceutical Industries Ltd (TARO.N) posted a 42 percent growth in October-December net profit.

Sun Pharma shares were up 3.5 percent as of 12:28 p.m.

(Reporting by Abhishek Vishnoi)

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.